<DOC>
	<DOC>NCT02715648</DOC>
	<brief_summary>The investigators propose to conduct a randomized controlled trial to evaluate whether administration of phenazopyridine prior to the procedure decreases office cystoscopy time. Women undergoing in-office cystoscopy at Boston Urogynecology will be recruited.</brief_summary>
	<brief_title>Using Phenazopyridine for In-office Cystoscopy</brief_title>
	<detailed_description>All potentially eligible participants will have had a complete history, physical examination, urinalysis and urine culture for clinical purposes. After eligibility is confirmed and written, informed consent is obtained, participants will be randomized to one of the two study arms. Participants randomized to phenazopyridine arm will receive 200 mg by mouth approximately 60 minutes prior to the scheduled cystoscopy. During the cystoscopy, at various time points, the time will be recorded.The color of the efflux will also be documented.</detailed_description>
	<criteria>Female patients undergoing inoffice diagnostic cystoscopy at Boston Urogynecology Associates Women who have taken vitamin B the day of the cystoscopy Cystoscopy with concurrent treatments such as botulinum toxin or periurethral bulking injections Allergy to phenazopyridine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>